| Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2012: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
|
|---|
| Outline of Final Research Achievements |
We developed novel antibodies against podoplanin expressing in lung squamous cell carcinoma and mesothelioma. We generated a human-rat chimeric anti-podoplanin antibody NZ-8 which showed higher anti-tumor activity in mouse xenograft model based on antibody-dependent cellular and complement- dependent cytotoxicity as compared to those of the rat antibody NZ-1. The binding activity of NZ-8 seemed to be higher against podoplanin expressing in tumor cells rather than normal cells such as alveolar cells or podocytes, indicating the advantage for clinical use of NZ-8. We finally developed the chimeric antibody NZ-12 showing the higher anti-tumor activity than NZ-8. Furthermore, gene expression analyses in xenograft tumors treated with NZ-1 identified the candidate genes related with the biological activity of NZ-1/NZ-8.
|
